AstraZeneca has partnered with biotechnology company insitro in a deal worth up to approximately $1.5 billion to discover potential treatments for difficult-to-treat liver and heart diseases using artificial intelligence.

Announced on October 15, 2026, the multi-year collaboration includes a $40 million upfront payment to insitro, with the potential for an additional $1.46 billion in milestone payments and royalties on future product sales.

The partnership will focus on metabolic dysfunction-associated steatohepatitis (MASH), a progressive liver disease, and cardiomyopathies, a group of conditions affecting the heart muscle.

The agreement highlights the pharmaceutical industry's growing interest in AI as a tool for understanding disease biology and identifying promising targets for new medicines.

Rather than using AI solely to speed up existing research processes, the companies aim to investigate the biological mechanisms that cause disease and determine which could offer the best opportunities for developing effective treatments.

How Insitro Plans to Use AI in Drug Discovery

Insitro will use its Virtual Human platform, which combines human biological data, laboratory-grown cellular models and machine learning to investigate the mechanisms underlying disease.

The platform is designed to help researchers identify causal relationships between biological processes and disease outcomes. These findings can then inform decisions about which targets to investigate during drug development.

Selecting the right biological target remains one of the major challenges in pharmaceutical research. Even when scientists understand the symptoms of a disease, identifying the specific processes responsible for its development or progression can be difficult.

AI systems can analyse large datasets, identify patterns and generate hypotheses that researchers can test through laboratory experiments.

When combined with experimental biology and scientific expertise, these capabilities could help researchers prioritise more promising targets before committing significant resources to development.

For AstraZeneca, the collaboration provides an opportunity to apply this approach to diseases where biological differences between patients can complicate treatment development.

However, identifying a potential target is only an early step. Researchers must still establish whether targeting a particular biological mechanism can produce a meaningful therapeutic benefit without unacceptable risks.

Why the Research Targets Liver and Heart Conditions

The partnership will investigate two areas of medicine where better understanding of disease mechanisms could help researchers develop additional treatment options.

MASH, or metabolic dysfunction-associated steatohepatitis, is a progressive condition associated with fat accumulation and inflammation in the liver. In some patients, the disease can lead to fibrosis, cirrhosis and other serious complications.

Cardiomyopathies are conditions that affect the structure or function of the heart muscle. Depending on the type, they can interfere with the heart's ability to pump blood and may contribute to heart failure or other complications.

Both disease categories involve complex biological processes, and patients can have different underlying characteristics despite sharing a diagnosis.

Insitro's approach seeks to use human and cellular data to investigate these differences and identify mechanisms that could become targets for future therapies.

The objective is to improve the selection of biological targets before drug candidates enter more advanced development.

The collaboration does not mean that AI has already produced new treatments for either condition. Any resulting candidates will need further research, testing and clinical evaluation before their safety and effectiveness can be established.

Inside the $1.5 Billion Agreement

The financial arrangement combines an upfront payment with additional compensation tied to research progress and potential commercial success.

Insitro will receive $40 million upfront and could earn up to approximately $1.46 billion in discovery, development and commercial milestone payments. It will also be eligible for royalties representing a single-digit percentage of future global sales of products developed through the collaboration.

The additional payments are conditional on achieving specified milestones, meaning the maximum potential value is not guaranteed revenue.

Under the agreement, insitro will use its platform to investigate disease biology and advance promising targets through to the development-candidate stage.

AstraZeneca will then lead and fund subsequent clinical trials, manage regulatory activities and oversee commercialisation.

This division of responsibilities brings together insitro's AI-enabled discovery capabilities and AstraZeneca's experience in pharmaceutical development and bringing medicines to market.

The structure also reflects a broader approach in biotechnology partnerships, where specialist research companies work with established pharmaceutical manufacturers to advance discoveries beyond the earliest stages of development.

AstraZeneca Expands Its AI Research Strategy

The collaboration adds to the pharmaceutical industry's efforts to incorporate machine learning and other AI techniques into drug research.

Drug development traditionally involves substantial time, investment and uncertainty. Many promising discoveries fail to become approved medicines because of safety concerns, insufficient effectiveness or difficulties during development.

AI could help researchers make more informed decisions at the discovery stage by analysing biological information and prioritising candidates for further investigation.

However, its value depends on the quality of the data, the reliability of the models and whether computational predictions hold up under experimental testing.

For AstraZeneca, the insitro partnership provides another opportunity to investigate whether AI-driven analysis can reveal disease mechanisms that conventional research approaches may overlook.

The collaboration also gives insitro access to a pharmaceutical partner with the resources needed to conduct clinical trials and pursue regulatory approval if suitable drug candidates emerge.

Insitro's Growing Pharmaceutical Partnerships

Insitro has been developing relationships with pharmaceutical companies seeking to apply machine learning to drug discovery.

Its collaborations have included work with Bristol Myers Squibb on research programmes involving amyotrophic lateral sclerosis (ALS) and a partnership with Eli Lilly focused on machine learning models for predicting how small-molecule drugs behave in living organisms.

These relationships illustrate how specialist biotechnology companies are combining computational methods with established pharmaceutical research capabilities.

Rather than replacing laboratory science, the approach seeks to use AI to guide experiments, identify patterns and help researchers decide where to concentrate resources.

The AstraZeneca agreement extends this strategy into MASH and cardiomyopathies, two disease areas where the identification of relevant biological targets could support future therapeutic development.

What the Deal Means for AI in Healthcare

The agreement demonstrates that pharmaceutical companies are willing to make substantial investments in AI-enabled research when it offers a potential route to discovering new treatments.

Yet the headline financial value should be viewed in context. Most of the potential payments depend on future milestones, and the partnership's ultimate scientific success remains uncertain.

AI can help identify patterns and prioritise research opportunities, but it cannot independently establish that a treatment is safe and effective for people. That requires experimental validation, clinical trials and regulatory assessment.

For patients with liver and heart diseases, the important outcome will not simply be the use of AI in research. It will be whether the collaboration produces medicines that improve treatment options and deliver meaningful clinical benefits.

For AstraZeneca and insitro, the partnership creates an opportunity to test whether combining human biological data, cellular models and machine learning can improve the path from disease research to potential medicines.